Drug Profile
SBR 759
Alternative Names: Phosphate binder - Novartis; SBR-759; SeborenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator SeBo GmbH
- Developer Novartis
- Class Disaccharides; Glucans; Iron compounds; Polymers
- Mechanism of Action Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperphosphataemia
Most Recent Events
- 01 Dec 2013 Discontinued - Phase-II for Hyperphosphataemia in Japan and Taiwan (PO)
- 31 Aug 2012 No development reported - Phase-III for Hyperphosphataemia in Japan (PO)
- 31 Dec 2007 Phase-II clinical trials in Hyperphosphataemia in Germany (PO)